Stabilizing Peri-Stent Restenosis Using a Novel Therapeutic Carrier

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Vascular Biology

Background:

• Late in-stent restenosis is a significant clinical challenge following peripheral artery stenting.
• Current treatments often require long-term antiplatelet therapy, which carries bleeding risks.

Purpose of the Study:

• To evaluate the efficacy of ultrasound-facilitated delivery of targeted nanoliposomes for reducing neointimal hyperplasia in stented peripheral arteries.
• To assess the combined therapeutic effect of nitric oxide and pioglitazone delivered via echogenic liposomes (ELIPs).

Main Methods:

• Bare-metal stents were implanted in miniature swine peripheral arteries.
• Nitric oxide-loaded ELIPs and anti-ICAM-1 conjugated ELIPs loaded with pioglitazone were infused.
• Ultrasound was used to facilitate targeted delivery of ELIPs to the stented region.

Main Results:

• Ultrasound-facilitated delivery of ELIP formulations significantly attenuated neointimal growth in stented arteries.
• The targeted delivery of nitric oxide and pioglitazone demonstrated a potential to stabilize stent-induced neointimal hyperplasia.

Conclusions:

• Local, ultrasound-triggered delivery of nitric oxide and pioglitazone via ELIPs is a promising strategy to manage in-stent restenosis.
• This approach could potentially obviate the need for prolonged antiplatelet therapy after stenting.